A detailed history of Tower Research Capital LLC (Trc) transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 5,218 shares of TBPH stock, worth $49,675. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,218
Previous 9,789 46.7%
Holding current value
$49,675
Previous $83,000 49.4%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.66 - $10.25 $35,013 - $46,852
-4,571 Reduced 46.7%
5,218 $42,000
Q2 2024

Aug 13, 2024

BUY
$8.29 - $9.92 $77,851 - $93,158
9,391 Added 2359.55%
9,789 $83,000
Q1 2024

May 15, 2024

SELL
$8.22 - $11.59 $188,533 - $265,828
-22,936 Reduced 98.29%
398 $3,000
Q4 2023

Feb 13, 2024

BUY
$8.58 - $11.4 $159,648 - $212,119
18,607 Added 393.63%
23,334 $262,000
Q3 2023

Nov 14, 2023

BUY
$8.38 - $10.44 $5,966 - $7,433
712 Added 17.73%
4,727 $40,000
Q2 2023

Aug 14, 2023

BUY
$10.16 - $11.92 $21,915 - $25,711
2,157 Added 116.09%
4,015 $41,000
Q1 2023

May 09, 2023

SELL
$9.87 - $11.44 $631 - $732
-64 Reduced 3.33%
1,858 $20,000
Q4 2022

Feb 10, 2023

SELL
$9.65 - $11.34 $76,765 - $90,209
-7,955 Reduced 80.54%
1,922 $21,000
Q3 2022

Nov 10, 2022

BUY
$8.39 - $10.22 $61,750 - $75,219
7,360 Added 292.41%
9,877 $100,000
Q2 2022

Aug 15, 2022

BUY
$8.41 - $10.34 $8,267 - $10,164
983 Added 64.08%
2,517 $23,000
Q1 2022

May 12, 2022

SELL
$8.33 - $12.96 $1,790 - $2,786
-215 Reduced 12.29%
1,534 $15,000
Q4 2021

Feb 14, 2022

SELL
$7.42 - $11.05 $13,059 - $19,448
-1,760 Reduced 50.16%
1,749 $19,000
Q3 2021

Nov 15, 2021

BUY
$6.77 - $14.41 $3,283 - $6,988
485 Added 16.04%
3,509 $26,000
Q2 2021

Aug 16, 2021

BUY
$14.52 - $22.46 $9,438 - $14,599
650 Added 27.38%
3,024 $44,000
Q1 2021

May 17, 2021

BUY
$16.57 - $21.08 $15,625 - $19,878
943 Added 65.9%
2,374 $48,000
Q4 2020

Feb 16, 2021

SELL
$14.89 - $20.16 $519,899 - $703,906
-34,916 Reduced 96.06%
1,431 $25,000
Q3 2020

Nov 16, 2020

BUY
$14.79 - $22.49 $415,717 - $632,148
28,108 Added 341.16%
36,347 $537,000
Q2 2020

Aug 13, 2020

BUY
$20.64 - $30.69 $170,052 - $252,854
8,239 New
8,239 $173,000
Q1 2020

May 15, 2020

SELL
$17.84 - $31.21 $55,196 - $96,563
-3,094 Closed
0 $0
Q4 2019

Feb 07, 2020

BUY
$16.12 - $25.89 $20,891 - $33,553
1,296 Added 72.08%
3,094 $80,000
Q3 2019

Nov 05, 2019

BUY
$16.51 - $23.78 $12,085 - $17,406
732 Added 68.67%
1,798 $35,000
Q2 2019

Aug 13, 2019

SELL
$15.6 - $25.15 $15 - $25
-1 Reduced 0.09%
1,066 $17,000
Q1 2019

May 14, 2019

BUY
$22.57 - $28.15 $15,054 - $18,776
667 Added 166.75%
1,067 $25,000
Q4 2018

Feb 14, 2019

BUY
$22.52 - $35.07 $9,008 - $14,028
400 New
400 $10,000
Q3 2018

Nov 13, 2018

SELL
$22.83 - $32.67 $11,940 - $17,086
-523 Closed
0 $0
Q2 2018

Aug 15, 2018

SELL
$22.06 - $25.52 $3,022 - $3,496
-137 Reduced 20.76%
523 $12,000
Q1 2018

May 15, 2018

BUY
$23.37 - $29.71 $2,664 - $3,386
114 Added 20.88%
660 $16,000
Q4 2017

Feb 09, 2018

SELL
$25.82 - $35.66 $157,708 - $217,811
-6,108 Reduced 91.79%
546 $15,000
Q3 2017

Nov 14, 2017

BUY
$23.88 - $34.96 $158,897 - $232,623
6,654
6,654 $227,000

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $636M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.